Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model

Journal of Clinical Biochemistry and Nutrition

Volumn 56, Issue 1, 2015, Pages 20-27

  Kurata, Satoshi ^a   Nakashima, Takako ^b   Osaki, Takako ^a   Uematsu, Naoya ^b   Shibamori, Masafumi ^b   Sakurai, Kazushi ^b   Kamiya, Shigeru ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Intestinal flora; Non steroidal anti inflammatory drugs; Oxidative stress; Rebamipide; Small intestine

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; CATHEPSIN; CATHEPSIN K; CATHEPSIN L1; COLLAGEN TYPE 4; COLLAGEN TYPE 5; CXCL3 CHEMOKINE; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 2; DUAL OXIDASE 2; EPIDERMAL GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LYMPHOTOXIN BETA; OXIDOREDUCTASE; PLASMINOGEN ACTIVATOR UROKINASE; REBAMIPIDE; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE; WNT5A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENTEROBACTERIACEAE; ENTEROCOCCACEAE; GENE EXPRESSION; ILEUM MUCOSA; INFLAMMATION; INTESTINE FLORA; INTESTINE INJURY; INTESTINE MUCOSA; JEJUNUM MUCOSA; LACTOBACILLUS; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WOUND HEALING;

CANDIDATUS ARTHROMITUS SP. SFB-MOUSE; ENTEROBACTERIACEAE; ENTEROCOCCACEAE; RATTUS;

EID: 84920399769     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.14-67     Document Type: Article

References (40)

1. Henry DA. Side-effects of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1988; 2: 425-454.
2. Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut 2008; 57: 145-148.
3. Iwai T, Ichikawa T, Kida M, et al. Vulnerable sites and changes in mucin in the rat small intestine after non-steroidal anti-inflammatory drugs administration. Dig Dis Sci 2010; 55: 3369-3376.
4. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol 2013; 19: 1861-1876.
5. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol 1996; 40: 553-560.
6. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960.
7. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-398.
8. Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med 2010; 123: 47-53.
9. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010; 4: 261-270.
10. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 1987; 142: 23-29.
11. Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci 2001; 46: 2277-2284.
12. Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 2009; 54: 1500-1507.
13. Kim HK, Kim JI, Kim JK, et al. Preventive effects of rebamipide on NSAIDinduced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 2007; 52: 1776-1782.
14. Park SH, Cho CS, Lee OY, et al. Comparison of prevention of NSAIDinduced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial - STORM STUDY. J Clin Biochem Nutr 2007; 40: 148-155.
15. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322.e5.
16. Yamamoto-Osaki T, Kamiya S, Sawamura S, Kai M, Ozawa A. Growth inhibition of Clostridium difficile by intestinal flora of infant faeces in continuous flow culture. J Med Microbiol 1994; 40: 179-187.
17. Osaki T, Matsuki T, Asahara T, et al. Comparative analysis of gastric bacterial microbiota in Mongolian gerbils after long-term infection with Helicobacter pylori. Microb Pathog 2012; 53: 12-18.
18. Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A 2004; 101: 1981-1986.
19. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol 2004; 70: 7220-7228.
20. Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K. Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription- PCR. Appl Environ Microbiol 2007; 73: 32-39.
21. Rinttilä T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 2004; 97: 1166-1177.
22. Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999; 40: 517-524.
23. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001; 16: 1112-1119.
24. Yamada S, Naito Y, Takagi T, et al. Rebamipide ameliorates indomethacininduced small intestinal injury in rats via the inhibition of matrix metalloproteinases activity. J Gastroenterol Hepatol 2012; 27: 1816-1824.
25. Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969; 54: 237-249.
26. Dalby AB, Frank DN, St. Amand AL, Bendele AM, Pace NR. Cultureindependent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota. Appl Environ Microbiol 2006; 72: 6707-6715.
27. Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Ohnishi Y. Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J Med Invest 2004; 51: 43-51.
28. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008; 57: 181-187.
29. Imaeda H, Fujimoto T, Takahashi K, Kasumi E, Fujiyama Y, Andoh A. Terminal-restriction fragment length polymorphism (T-RFLP) analysis for changes in the gut microbiota profiles of indomethacin- and rebamipidetreated mice. Digestion 2012; 86: 250-257.
30. Tanigawa T, Watanabe T, Otani K, et al. Rebamipide inhibits indomethacininduced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of defensin 5. Eur J Pharmacol 2013; 704: 64-69.
31. Lacombe A, Li RW, Klimis-Zacas D, et al. Lowbush wild blueberries have the potential to modify gut microbiota and xenobiotic metabolism in the rat colon. PLoS One 2013; 8: e67497.
32. Umesaki Y, Setoyama H, Matsumoto S, Imaoka A, Itoh K. Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun 1999; 67: 3504-3511.
33. Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32: 815-827.
34. Bertrand V, Guimbaud R, Tulliez M, et al. Increase in tumor necrosis factor- production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998; 124: 1385-1394.
35. El Hassani RA, Benfares N, Caillou B, et al. Dual oxidase2 is expressed all along the digestive tract. Am J Physiol Gastrointest Liver Physiol 2005; 288: G933-G942.
36. Endo H, Higurashi T, Hosono K, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011; 46: 894-905.
37. Matsumoto S, Hara T, Hori T, et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005; 140: 417-426.
38. Ingrassia I, Leplingard A, Darfeuille-Michaud A. Lactobacillus casei DN- 114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol 2005; 71: 2880-2887.
39. Iwai T, Ichikawa T, Kida M, et al. Protective effect of geranylgeranylacetone against loxoprofen sodium-induced small intestinal lesions in rats. Eur J Pharmacol 2011; 652: 121-125.
40. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. Pharmacologic targeting of bacterial glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 2012; 341: 447-454.